Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2021-2031F

The Global market for next-generation biotherapeutics is anticipated to expand from USD 5.71 billion in 2025 to USD 11.65 billion by 2031, reflecting a compound annual growth rate of 12.62%. These advanced treatments involve sophisticated biological systems and molecules sourced from living organisms, encompassing gene and cell therapies, monoclonal antibodies, and oligonucleotide therapeutics. They are formulated to provide highly targeted treatments for ailments such as genetic disorders, cancer, and autoimmune diseases. Growth in this sector is primarily fueled by the rising global incidence of rare and chronic illnesses that necessitate novel medical solutions, alongside major technological strides and boosted funding in biopharmaceutical research and development.

However, continuous market growth is significantly hindered by the steep expenses tied to creating, producing, and distributing these intricate biological treatments. Data from the Pharmaceutical Research and Manufacturers of America indicates that out of 52 new medicines approved in 2025, only six were novel vaccines and biologics. Additionally, the Biotechnology Innovation Organization highlighted in 2025 that financial backing for biotech startups dropped sharply from $2.6 billion in the first quarter to $900 million by the second quarter, emphasizing the tight financial conditions currently impacting the industry.

Market Driver

Progress in therapeutic technologies and biotechnology is significantly transforming the next-generation biotherapeutics industry by facilitating the creation of highly complex medical interventions. Breakthroughs in RNA-based treatments, cell therapy, and gene editing are broadening the range of conditions that can be treated while introducing innovative mechanisms of action. Consequently, an expanding portfolio of sophisticated biological treatments is successfully navigating the regulatory approval process. As noted by Contract Pharma on March 2, 2026, in its report "The 2026 Biologics Wave: Which Innovations Will Break Through?", the CDER had authorized 46 new drug therapies by the close of 2025, a dozen of which were biologics. This trend highlights the growing viability and advancement of next-generation biotherapeutics, which in turn draws more funding and skilled professionals to the field.

An additional major catalyst for this global market is the rising need for customized and highly targeted medical therapies, which signifies a major shift toward individualized patient healthcare. This surge in demand is driven by a more profound comprehension of disease variations and the capacity of these advanced therapies to deliver better results with fewer adverse effects than traditional options. These individualized strategies are especially crucial in challenging medical fields such as rare diseases and oncology. A MarketWatch report from March 27, 2026, titled "Personalized Medicine Market Share & Opportunities 2026-2033," predicts that North America will capture 44.4% of the personalized medicine sector in 2026, demonstrating strong regional uptake. Moreover, massive investments are flowing into the wider biopharmaceutical arena, with Fierce Biotech reporting in 2026 that major pharma corporations spent over $36 billion on biotech buyouts during just October and November of 2025, thereby sustaining the innovation and infrastructure needed to deliver these modern treatments worldwide.

Market Challenge

The immense financial requirements for researching, producing, and distributing next-generation biotherapeutics create a major hurdle for the growth of this market. Because these advanced treatments require in-depth scientific study, custom-built manufacturing centers, and rigorous regulatory compliance, the overall expenditures are exceptionally high. Consequently, this financial strain leads to exorbitant prices for the final therapies, which can restrict availability for a wider range of patients and ultimately hinder broader market acceptance and overall utilization.

Additionally, the massive financial investment necessary to advance these therapies presents a formidable obstacle for emerging biotech startups and smaller enterprises. Obtaining the requisite capital to support lengthy research phases and expansive production efforts proves difficult, especially when investors require rigorous proof of concept beforehand. Data from the Massachusetts Biotechnology Council shows that venture capital funding for companies based in Massachusetts reached $6.85 billion over 197 investment rounds in 2025. Although these figures indicate a recovery to numbers seen before the pandemic, they also highlight a fiercely competitive funding environment that can delay the journey of groundbreaking treatments from the laboratory to the commercial market.

Market Trends

Incorporating artificial intelligence into the creation of new medicines is drastically altering the global next-generation biotherapeutics sector by speeding up discovery and boosting research and development productivity. By moving past conventional lab techniques, this movement utilizes advanced computing to quickly pinpoint new drug targets, engineer better molecules, and forecast both safety and effectiveness. These AI applications are modernizing the initial phases of pharmaceutical development, fostering a more adaptable and data-centric approach. Illustrating the industry's strong confidence in this technological evolution, Eli Lilly and NVIDIA declared in January 2026 that they would co-invest up to $1 billion over a five-year period to establish an AI-driven laboratory dedicated to discovering novel drugs.

A parallel major trend is the rise of localized and point-of-care biological manufacturing systems, which play a vital role in effectively creating and supplying cutting-edge treatments, especially those tailored for rare conditions and personalized medicine. This transition circumvents the high costs and logistical difficulties of massive, centralized production by utilizing compact, adaptable facilities situated near patients or dedicated care facilities. Such frameworks capitalize on advancements like continuous manufacturing to lower the massive upfront investments typically needed to produce biologics. As highlighted by MedCity News on January 29, 2026, utilizing continuous manufacturing methods can shrink the required equipment space by as much as 70%, rendering these decentralized production networks much more cost-effective and functionally beneficial.

Key Market Players

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

Report Scope

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area

• Oncology
• Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology

• Antibody-Drug Conjugates
• Bispecific Antibodies
• Antibody Fragments
• Antibody-like Proteins
• Others

Next Generation Biotherapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).